CD274 and metastatic colorectal cancer: Currently, many other cancers such as renal carcinoma, colorectal cancer, lymphoma, head and neck carcinoma, bladder cancer, hepatocellular carcinoma and metastatic colorectal cancer are also approved for PD-1/PD-L1-targeting therapy (Ansell et al., 2015; Le et al., 2015; Ferris et al., 2016; Bellmunt et al., 2017; Motzer et al., 2018; Overman et al., 2018).